BBA FCA - POINT Biopharma Chief Officer
| PNTDelisted Stock | USD 9.06 0.10 1.09% |
Insider
BBA FCA is Chief Officer of POINT Biopharma Global
| Age | 64 |
| Phone | 647 812 2417 |
| Web | https://www.pointbiopharma.com |
POINT Biopharma Management Efficiency
The company has Return on Asset of 0.1677 % which means that on every $100 spent on assets, it made $0.1677 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2633 %, implying that it generated $0.2633 on every 100 dollars invested. POINT Biopharma's management efficiency ratios could be used to measure how well POINT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.POINT Biopharma Global has 3.56 M in debt with debt to equity (D/E) ratio of 0.01, which may show that the company is not taking advantage of profits from borrowing. POINT Biopharma Global has a current ratio of 10.68, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for POINT to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| David Chao | Centessa Pharmaceuticals PLC | 56 | |
| Harpreet Singh | Immatics NV | 49 | |
| MD MBA | Opthea | N/A | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| MD MSc | Centessa Pharmaceuticals PLC | 64 | |
| Scott Smith | Bioatla | 62 | |
| Linda Fitzpatrick | Sutro Biopharma | 67 | |
| Julie Person | Third Harmonic Bio | 50 | |
| Sophia MD | Alx Oncology Holdings | 56 | |
| Jack Anders | Revolution Medicines | 47 | |
| Karen Anderson | Centessa Pharmaceuticals PLC | 56 | |
| Rainer Kramer | Immatics NV | 59 | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Natalie Holles | Third Harmonic Bio | 51 | |
| Gwen Carscadden | RAPT Therapeutics | 63 | |
| BS CPA | Inhibrx | 42 | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Timothy MBA | Aerovate Therapeutics | 62 | |
| Philippe Martin | Bioatla | 48 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Edward MD | Third Harmonic Bio | 51 | |
Management Performance
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 |
POINT Biopharma Global Leadership Team
Elected by the shareholders, the POINT Biopharma's board of directors comprises two types of representatives: POINT Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of POINT. The board's role is to monitor POINT Biopharma's management team and ensure that shareholders' interests are well served. POINT Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, POINT Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MPH MPH, Ex Devel | ||
| FRCSC MD, Chief Director | ||
| Ari Shomair, VP Staff | ||
| Joe McCann, CEO Director | ||
| Donna BA, VP HR | ||
| RPh Herle, Ex Affairs | ||
| BBA FCA, Chief Officer | ||
| Todd BE, Ex Operations | ||
| Justyna MSc, Chief Officer | ||
| Allan Silber, Ex Chairman | ||
| Dr JD, Sr Devel |
POINT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is POINT Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | (10.62) % | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 106.57 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 48.91 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Book | 3.13 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |